Business Daily Media

Men's Weekly

.

Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets (Safinamide Mesilate) in Japan from Meiji Seika Pharma

  • Written by ACN Newswire - Press Releases

Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets (Safinamide Mesilate) in Japan from Meiji Seika Pharma

TOKYO, Sep 7, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will take over by transfer the manufacturing and marketing approval of Parkinson's disease treatment Equfina 50mg TABLETS (safinamide mesilate, "Equfina") in Japan from Meiji Seika Pharma Co., Ltd., effective September 23, 2020.

In Japan, Meiji conducted clinical

Read more //?#

Australian companies pitching to the world’s wealthiest investors

#CapTech 2025 to bring world investors to Australia’s doorstep  One of Australia’s leading business and capital events is bringing together inves...

Small business backlash builds as RBA’s surcharge ban risks fuelling inflation

Australia’s small business sector has launched a fierce campaign against the Reserve Bank of Australia’s (RBA) proposed ban on debit and credit card...

Australia’s Young Entrepreneurs Redefining Success Through Legacy and Community Impact

A new generation of young Australian small business owners is redefining success, driven by a desire to create a lasting legacy through the positi...

Lessons in AI: How LoanOptions.ai Shows What Smart Adoption Really Looks Like

In a world where many small businesses are still trying to work out how to actually use AI (not just talk about it), Australian fintech LoanOption...

Driving smarter: how car subscription models are redefining mobility and financial flexibility

The world of mobility is changing fast, and car ownership is no longer the default. Across Australia, professionals and businesses alike are seeki...

The Future of Wealth Technology

“You shouldn’t need a large account balance to experience real-time investing. Technology should make that kind of access universal.” For decades...